Inactivated Poliomyelitis Vaccine (Salk strains)

also known as Salk IPV

Developed for: poliomyelitis
Investigated by: Guangxi Center for Disease Control and Prevention · National Institute for the Control of Pharmaceutical and Biological Products, China · Chinese Academy of Medical Sciences · Institute of Medical Biology, Chinese Academy of Medical Sciences

today NCT01510366 · Ph 3 NCT01056705 · Ph 2

201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 21 trial
Phase 2	NCT01056705	Jul 2009 → May 2010	poliomyelitis	Chinese Academy of Medical Sciences	Completed	No outcome recorded
Phase 31 trial
Phase 3	NCT01510366	Jan 2012 → Sep 2015	poliomyelitis	Institute of Medical Biology, Chinese Academy of Medical Sciences	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT04073459 Comparator	Nov 2019 → Apr 2020	diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +2	LG Chem	Unknown	No outcome recorded

Every value below carries the sentence it was read from. 3 sources stand behind the page.

Field	Value	Cited text
Known as	Inactivated Poliomyelitis Vaccine (Salk strains)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01510366 ↗ 1 NCT01056705 ↗
Known as	Salk IPV	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04073459 ↗
Modality	Vaccine	“Inactivated Poliomyelitis Vaccine (Salk strains)was manufactured by Sanofi Pasteur DAg contents /0.5ml/per dose were Type 1 40 DU,Type 2 8DU,Type 3 32DU.” NCT01056705 ↗
Route	Intramuscular	“3 x 0.5ml intramuscular injections” NCT01510366 ↗